Integrating Escherichia coli Antimicrobial Susceptibility Data from Multiple Surveillance Programs
John M. Stelling*† , Karin Travers*, Ronald N. Jones‡§, Philip J. Turner¶, Thomas F. O'Brien*†, and Stuart B. Levy*§
Author affiliations: *Alliance for the Prudent Use of Antibiotics, Boston, Massachusetts, USA; †Brigham and Women's Hospital, Boston, Massachusetts, USA; ‡The Jones Group, North Liberty, Iowa, USA; §Tufts University, Boston, Massachusetts, USA; ¶AstraZeneca, Macclesfield, Cheshire, United Kingdom
Figure 1. . Comparison of MYSTIC and SENTRY rates of Escherichia coli nonsusceptibility rates in 2001 to antimicrobial drugs tested by both networks. Significant findings are indicated with an asterisk where the MYSTIC estimate is higher than the SENTRY result and with a plus sign when the SENTRY estimate is higher. Country codes are the official 3-letter codes designated by the International Organization for Standardization: BEL, Belgium; CAN, Canada; DEU, Germany; ESP, Spain; GBR, United Kingdom; GRC, Greece; ITA, Italy; SWE, Sweden; TUR, Turkey; and USA, United States.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.